Oral roflumilast as a therapeutic option for psoriasis, what role does it have? Case report and literature review

Figures & data

Figure 1. (A–D) Clinical presentation of the cutaneous lesions before initiating oral roflumilast. Scalp is especially affected, associated with moderate pruritus (consent from the patient was obtained).

Figure 2. (A–D) No lesions are observed after 8 weeks of oral roflumilast (consent from the patient was obtained).

Table 1. Previously reported cases of psoriasis treated with oral roflumilast.

	Type of study	Age	Sex	Psoriasis type	Comorbidities	Side effects	Outcome
Gyldenløve et al. (2023)	Clinical trial	Median of 38 years	15 Male 8 female	Plaque psoriasis	Not reported	Mainly weight loss in 19 patients, decreased appetite in 14, nausea in 12, headache in 11 and abdominal pain in 9.	At week 24: 10 patients PASI 75 5 patients PASI 90 2 patients PASI 100
Gyldenløve et al. (2023)	Case report	48	Male	Plaque psoriasis	Overweight and obstructive lung disease	Weight reduction and transient gastrointestinal symptoms	Complete clearance after 6 months.
Ring et al. (2022)	Case report	54	Male	Plaque psoriasis.	Overweight and suppurative hidradenitis.	Weight reduction.	Complete clearing of psoriasis and improvement of hidradenitis after 5 months.
Michels et al. (2017)	Case report	59	Male	Plaque psoriasis, erythroderma	Chronic obstructive pulmonary disease	Not reported.	Improvement (treated as well with triamcinolone and intravenous methylprednisolone, but still presenting some plaques.

No special locations such as genital area, palms and soles or scalp were described as affected.

Data availability statement

Data sharing not applicable – no new data generated.